Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure

Journal of the American College of Cardiology

Volumn 69, Issue 11, 2017, Pages 1399-1406

  Felker, G Michael ^a,b   Mentz, Robert J ^a,b   Cole, Robert T ^c   Adams, Kirkwood F ^d   Egnaczyk, Gregory F ^e   Fiuzat, Mona ^a,b   Patel, Chetan B ^a,b   Echols, Melvin ^a   Khouri, Michel G ^a   Tauras, James M ^f   Gupta, Divya ^c   Monds, Pamela ^a,b   Roberts, Rhonda ^a,b   O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CHRIST HOSPITAL   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

acute heart failure; decongestion; outcomes; strategies; volume overload

Indexed keywords

FUROSEMIDE; PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERNATREMIA; HYPONATREMIA; KIDNEY FUNCTION; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; WEIGHT REDUCTION; HEART FAILURE; KIDNEY FUNCTION TEST; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85015226208     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.004     Document Type: Article

References (27)

1. 1 Gheorghiade, M., Follath, F., Ponikowski, P., et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 12 (2010), 423–433.
2. 2 Mullens, W., Abrahams, Z., Francis, G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 (2009), 589–596.
3. 3 Ambrosy, A.P., Pang, P.S., Khan, S., et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34 (2013), 835–843.
4. 4 Mentz, R.J., Kjeldsen, K., Rossi, G.P., et al. Decongestion in acute heart failure. Eur J Heart Fail 16 (2014), 471–482.
5. 5 Chen, H.H., Anstrom, K.J., Givertz, M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310 (2013), 2533–2543.
6. 6 Bart, B.A., Goldsmith, S.R., Lee, K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 (2012), 2296–2304.
7. 7 Gheorghiade, M., Gattis, W.A., O'Connor, C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004), 1963–1971.
8. 8 Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
9. 9 Gheorghiade, M., Konstam, M.A., Burnett, J.C. Jr., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007), 1332–1343.
10. 10 Pang, P.S., Konstam, M.A., Krasa, H.B., et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 30 (2009), 2233–2240.
11. 11 Hauptman, P.J., Burnett, J., Gheorghiade, M., et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19 (2013), 390–397.
12. 12 Felker, G.M., Mentz, R.J., Adams, K.F., et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail 8 (2015), 997–1005.
13. 13 Felker, G.M., Lee, K.L., Bull, D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
14. 14 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
15. 15 Massie, B.M., O'Connor, C.M., Metra, M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363 (2010), 1419–1428.
16. 16 Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
17. 17 Matsue, Y., Suzuki, M., Torii, S., et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22 (2016), 423–432.
18. 18 Kociol, R.D., McNulty, S.E., Hernandez, A.F., et al. Markers of decongestion, dyspnea relief and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 6 (2013), 240–245.
19. 19 Pang, P.S., Cleland, J.G., Teerlink, J.R., et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 29 (2008), 816–824.
20. 20 Miller, W.L., Mullan, B.P., Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. J Am Coll Cardiol HF 2 (2014), 298–305.
21. 21 Butler, J., Gheorghiade, M., Kelkar, A., et al. In-hospital worsening heart failure. Eur J Heart Fail 17 (2015), 1104–1113.
22. 22 Davison, B.A., Metra, M., Cotter, G., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. J Am Coll Cardiol HF 3 (2015), 395–403.
23. 23 Kelly, J.P., Mentz, R.J., Hasselblad, V., et al. Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am Heart J 170 (2015), 298–305.
24. 24 Metra, M., Davison, B., Bettari, L., et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 (2012), 54–62.
25. 25 Testani, J.M., Brisco, M.A., Chen, J., McCauley, B.D., Parikh, C.R., Tang, W.H., Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 62 (2013), 516–524.
26. 26 Irazabal, M.V., Torres, V.E., Hogan, M.C., et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80 (2011), 295–301.
27. 27 Boertien, W.E., Meijer, E., de Jong, P.E., et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 84 (2013), 1278–1286.